OTCMKTS:GTHP

Guided Therapeutics Competitors

$0.80

-0.02 (-2.44 %)

(As of 04/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.69

Now: $0.80▼

$0.83

50-Day Range

$0.71

MA: $0.79▼

$0.90

52-Week Range

$0.12

Now: $0.80▼

$1.00

Volume7,439 shs

Average Volume18,461 shs

Market Capitalization$10.54 million

P/E RatioN/A

Dividend YieldN/A

Beta0.8

Guided Therapeutics (OTCMKTS:GTHP) Vs. HSDT, FCRE, CHFS, VIVE, RSLS, and PEYE

Should you be buying GTHP stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Guided Therapeutics, including Helius Medical Technologies (HSDT), Fc Global Realty (FCRE), CHF Solutions (CHFS), Viveve Medical (VIVE), ReShape Lifesciences (RSLS), and Precision Optics (PEYE).

Guided Therapeutics vs. Helius Medical Technologies Stock

Guided Therapeutics (OTCMKTS:GTHP) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Profitability

This table compares Guided Therapeutics and Helius Medical Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	-29.31%	502.80%
Helius Medical Technologies	-2,716.85%	-328.07%	-201.87%

Volatility & Risk

Guided Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Guided Therapeutics and Helius Medical Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Helius Medical Technologies	0	1	2	0	2.67

Helius Medical Technologies has a consensus target price of $20.00, suggesting a potential upside of 13.90%. Given Helius Medical Technologies' higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than Guided Therapeutics.

Valuation & Earnings

This table compares Guided Therapeutics and Helius Medical Technologies' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guided Therapeutics	$40,000.00	263.60	$-1,920,000.00	N/A	N/A
Helius Medical Technologies	$1.50 million	27.05	$-9,780,000.00	($12.94)	-1.36

Guided Therapeutics has higher earnings, but lower revenue than Helius Medical Technologies.

Summary

Guided Therapeutics beats Helius Medical Technologies on 6 of the 10 factors compared between the two stocks.

Guided Therapeutics vs. Fc Global Realty Stock

Fc Global Realty (OTCMKTS:FCRE) and Guided Therapeutics (OTCMKTS:GTHP) are both small-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Risk & Volatility

Fc Global Realty has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Valuation & Earnings

This table compares Fc Global Realty and Guided Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fc Global Realty	$40,000.00	971.79	$-2,040,000.00	N/A	N/A
Guided Therapeutics	$40,000.00	263.60	$-1,920,000.00	N/A	N/A

Profitability

This table compares Fc Global Realty and Guided Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fc Global Realty	-4,265.28%	-24.94%	-9.42%
Guided Therapeutics	N/A	-29.31%	502.80%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Fc Global Realty and Guided Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fc Global Realty	0	0	0	0	N/A
Guided Therapeutics	0	0	0	0	N/A

Guided Therapeutics vs. CHF Solutions Stock

Guided Therapeutics (OTCMKTS:GTHP) and CHF Solutions (NASDAQ:CHFS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Guided Therapeutics and CHF Solutions' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	-29.31%	502.80%
CHF Solutions	-254.26%	-173.61%	-131.01%

Risk & Volatility

Guided Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, CHF Solutions has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Institutional & Insider Ownership

65.1% of CHF Solutions shares are held by institutional investors. 76.3% of Guided Therapeutics shares are held by insiders. Comparatively, 0.6% of CHF Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Guided Therapeutics and CHF Solutions' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guided Therapeutics	$40,000.00	263.60	$-1,920,000.00	N/A	N/A
CHF Solutions	$5.51 million	5.84	$-18,110,000.00	($279.28)	-0.02

Guided Therapeutics has higher earnings, but lower revenue than CHF Solutions.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Guided Therapeutics and CHF Solutions, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
CHF Solutions	0	0	1	0	3.00

CHF Solutions has a consensus price target of $20.00, indicating a potential upside of 275.23%. Given CHF Solutions' higher possible upside, analysts clearly believe CHF Solutions is more favorable than Guided Therapeutics.

Guided Therapeutics vs. Viveve Medical Stock

Guided Therapeutics (OTCMKTS:GTHP) and Viveve Medical (NASDAQ:VIVE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Guided Therapeutics and Viveve Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Viveve Medical	0	0	1	0	3.00

Earnings and Valuation

This table compares Guided Therapeutics and Viveve Medical's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guided Therapeutics	$40,000.00	263.60	$-1,920,000.00	N/A	N/A
Viveve Medical	$6.57 million	4.74	$-42,530,000.00	($338.00)	-0.01

Guided Therapeutics has higher earnings, but lower revenue than Viveve Medical.

Profitability

This table compares Guided Therapeutics and Viveve Medical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	-29.31%	502.80%
Viveve Medical	-661.57%	-243.62%	-139.23%

Institutional & Insider Ownership

18.2% of Viveve Medical shares are held by institutional investors. 76.3% of Guided Therapeutics shares are held by insiders. Comparatively, 5.0% of Viveve Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Guided Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Viveve Medical has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Summary

Guided Therapeutics beats Viveve Medical on 7 of the 11 factors compared between the two stocks.

Guided Therapeutics vs. ReShape Lifesciences Stock

Guided Therapeutics (OTCMKTS:GTHP) and ReShape Lifesciences (OTCMKTS:RSLS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Guided Therapeutics and ReShape Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guided Therapeutics	$40,000.00	263.60	$-1,920,000.00	N/A	N/A
ReShape Lifesciences	$15.09 million	1.80	$-74,210,000.00	N/A	N/A

Guided Therapeutics has higher earnings, but lower revenue than ReShape Lifesciences.

Volatility and Risk

Guided Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.

Profitability

This table compares Guided Therapeutics and ReShape Lifesciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	-29.31%	502.80%
ReShape Lifesciences	-314.18%	-186.31%	-101.10%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Guided Therapeutics and ReShape Lifesciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
ReShape Lifesciences	0	0	1	0	3.00

Summary

Guided Therapeutics beats ReShape Lifesciences on 5 of the 8 factors compared between the two stocks.

Guided Therapeutics vs. Precision Optics Stock

Precision Optics (OTCMKTS:PEYE) and Guided Therapeutics (OTCMKTS:GTHP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Precision Optics and Guided Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision Optics	0	0	0	0	N/A
Guided Therapeutics	0	0	0	0	N/A

Valuation and Earnings

This table compares Precision Optics and Guided Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision Optics	$9.92 million	2.17	$-1,430,000.00	N/A	N/A
Guided Therapeutics	$40,000.00	263.60	$-1,920,000.00	N/A	N/A

Precision Optics has higher revenue and earnings than Guided Therapeutics.

Profitability

This table compares Precision Optics and Guided Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precision Optics	-13.17%	-46.31%	-22.21%
Guided Therapeutics	N/A	-29.31%	502.80%

Risk & Volatility

Precision Optics has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Summary

Guided Therapeutics beats Precision Optics on 6 of the 8 factors compared between the two stocks.